What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Psoriasis
His primary areas of investigation include Psoriasis, Internal medicine, Psoriasis Area and Severity Index, Placebo and Randomized controlled trial.
His studies deal with areas such as Intensive care medicine, Adverse effect, Surgery and Etanercept as well as Psoriasis.
Visual analogue scale is closely connected to Efalizumab in his research, which is encompassed under the umbrella topic of Psoriasis Area and Severity Index.
His Placebo research focuses on Intention-to-treat analysis and how it relates to Chemotherapy and Body surface area.
His study on Randomized controlled trial also encompasses disciplines like
- Severity of illness which connect with Dermatology Life Quality Index and Dose,
- Physical therapy that connect with fields like Beck Depression Inventory.
His Tildrakizumab study combines topics in areas such as Guselkumab and Risankizumab.
His most cited work include:
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) (1468 citations)
- Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics (923 citations)
- Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial (820 citations)
What are the main themes of his work throughout his whole career to date?
Kenneth B. Gordon mostly deals with Psoriasis, Internal medicine, Dermatology, Psoriasis Area and Severity Index and Placebo.
His Psoriasis research integrates issues from Randomized controlled trial, Surgery, Adalimumab and Clinical trial.
His study in Ustekinumab, Adverse effect, Severity of illness, Guselkumab and Plaque psoriasis is carried out as part of his Internal medicine studies.
His Dermatology research incorporates elements of Moderate to severe and Infliximab, Disease.
His studies in Psoriasis Area and Severity Index integrate themes in fields like Dermatology Life Quality Index and Body surface area.
His research in Placebo intersects with topics in Quality of life, Risankizumab and Ixekizumab.
He most often published in these fields:
- Psoriasis (71.71%)
- Internal medicine (41.04%)
- Dermatology (32.27%)
What were the highlights of his more recent work (between 2018-2021)?
- Psoriasis (71.71%)
- Internal medicine (41.04%)
- Plaque psoriasis (13.94%)
In recent papers he was focusing on the following fields of study:
Kenneth B. Gordon spends much of his time researching Psoriasis, Internal medicine, Plaque psoriasis, Psoriasis Area and Severity Index and Dermatology.
His Psoriasis study incorporates themes from Randomized controlled trial and Intensive care medicine.
Kenneth B. Gordon usually deals with Internal medicine and limits it to topics linked to Placebo and Phases of clinical research.
His work carried out in the field of Plaque psoriasis brings together such families of science as Certolizumab pegol and Tildrakizumab.
In his research, Autoinjector and Subcutaneous injection is intimately related to Clinical trial, which falls under the overarching field of Psoriasis Area and Severity Index.
Kenneth B. Gordon works mostly in the field of Dermatology, limiting it down to topics relating to Disease and, in certain cases, Drug, as a part of the same area of interest.
Between 2018 and 2021, his most popular works were:
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. (169 citations)
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities (75 citations)
- A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. (30 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Psoriasis
His primary areas of study are Psoriasis, Psoriasis Area and Severity Index, Internal medicine, Intensive care medicine and Guideline.
As part of his studies on Psoriasis, Kenneth B. Gordon often connects relevant subjects like Randomized controlled trial.
Psoriasis Area and Severity Index is a subfield of Dermatology that Kenneth B. Gordon studies.
Internal medicine is closely attributed to Placebo in his work.
His work on BLINDED TREATMENT as part of general Placebo study is frequently linked to Markov chain Monte Carlo methodology, bridging the gap between disciplines.
In his work, Psoriatic arthritis, Odds ratio, Inflammatory bowel disease and Biologic Agents is strongly intertwined with Quality of life, which is a subfield of Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
